- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02558088
Pharmacological Properties of Salmeterol
January 29, 2017 updated by: Morten Nielsen, University of Copenhagen
Pharmacological Properties of Inhaled Salmeterol in Healthy Trained Males
The objective of the study is to help establish a urinary threshold for salmeterol on the World Anti-doping Agency prohibited list, to avoid supratherapeutic of this substance in competitive sports.
Hence, there is no hypothesis as such.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Select State
-
Copenhagen, Select State, Denmark, 2400
- Bispebjerg Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male
- 18-45 years
- Healthy
Exclusion Criteria:
- Chronic disease
- Smoking
- Habitual use of medicine
- Allergy towards salmeterol
- Unable to exercise on a bike ergometer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: salmeterol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urine concentration of salmeterol
Time Frame: 0-24 hours after administration of the study drug
|
0-24 hours after administration of the study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
July 1, 2016
Study Registration Dates
First Submitted
September 12, 2015
First Submitted That Met QC Criteria
September 22, 2015
First Posted (Estimate)
September 23, 2015
Study Record Updates
Last Update Posted (Estimate)
January 31, 2017
Last Update Submitted That Met QC Criteria
January 29, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Salmeterol Xinafoate
Other Study ID Numbers
- WADA2013sal
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacokinetics in Healthy Young Men
-
King's College LondonNaturex-DbsCompleted
-
H. Lundbeck A/SCompletedHealthy Young MenSweden
-
University of Rennes 2RecruitingHealthy Young Women | Healthy Young MenFrance
-
University of LimerickMarigot Ltd.; Enterprise IrelandCompletedBioavailability of Amino Acids Following Oral Ingestion of Plant-Based Proteins in Young, Healthy MenIreland
-
University of the French West Indies and French...CompletedHealthy and Physically Active Young MenFrance
-
University of CopenhagenUnknown
-
University of CopenhagenBispebjerg Hospital; University of Southern DenmarkCompletedMuscle Hypertrophy in Healthy Young Men
-
University of TorontoCompletedGlycemic Control | Healthy Young Men | Gastrointestinal Hormone ResponseCanada
-
University of Alabama, TuscaloosaEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingSecond Language Acquisition in Healthy Young AdultsUnited States
-
Daiichi Sankyo, Inc.CompletedPharmacokinetics in Healthy VolunteersUnited States
Clinical Trials on Salmeterol
-
Boehringer IngelheimTerminatedPulmonary Disease, Chronic ObstructiveUnited States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, South Africa, Sweden
-
Boehringer IngelheimTerminatedPulmonary Disease, Chronic ObstructiveUnited States, Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, Sweden
-
Arthur F Gelb MDCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
GlaxoSmithKlineWithdrawnPulmonary Disease, Chronic Obstructive
-
Boehringer IngelheimCompleted
-
Neovii BiotechFresenius Biotech North AmericaCompletedOvarian CancerUnited States
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveGermany
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseChina, Argentina, Taiwan, Chile